Autres langues Clene Inc.

Actions

CLNN

US1856341029

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,4349 ^USD	-0,41%		+27,95%	+46,63%

16/04	Clene Inc. et Clene Nanomedicine, Inc. ont présenté les résultats de l'étude de phase 2 VISIONARY-MS Long term Extension (LTE) lors de la réunion annuelle de l'American Academy of Neurology (AAN) qui s'est tenue à Denver en 2024.	CI
15/03	Clene Inc. annonce une publication évaluée par des pairs caractérisant la couronne protéique du médicament expérimental contre les maladies neurodégénératives, le CNM-Au8.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington	01/05
Clene : 2023 Annual Report to Stockholders	17/04
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	16/04
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	16/04
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	19/03
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	15/03
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	15/03
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	13/03
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
North American Morning Briefing : Stock Futures -2-	11/03
Clene to Present at the 36th Annual ROTH Conference	07/03
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	29/02
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	22/02
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	22/02
Clene Inc. announces positive results from CNM-Au8 results from MS trial	05/02
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	08/01
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	08/01
US FDA finds Clene's trial data for ALS drug to be insufficient	21/12
Clene Provides Update on ALS Clinical Development Meeting With FDA	21/12
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	21/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clene Inc.

Actions

CLNN

US1856341029

Autres langues

Filtres